NASDAQ:NTRP NextTrip 11/13/2023 Earnings Report ProfileEarnings HistoryForecast NextTrip EPS ResultsActual EPS-$1.57Consensus EPS -$1.80Beat/MissBeat by +$0.23One Year Ago EPSN/ANextTrip Revenue ResultsActual Revenue$0.14 millionExpected Revenue$0.57 millionBeat/MissMissed by -$430.00 thousandYoY Revenue GrowthN/ANextTrip Announcement DetailsQuarterDate11/13/2023TimeN/AConference Call DateN/AConference Call TimeN/AConference Call ResourcesEarnings HistoryCompany Profile NextTrip Earnings HeadlinesNextTrip, Inc. Reports Second Quarter Financial ResultsOctober 17 at 4:20 AM | finanznachrichten.deNextTrip, Inc. Reports Second Quarter Financial ResultsOctober 17 at 4:20 AM | finanznachrichten.deShots officially fired…Elon Musk just declared war on the wireless giants with a $17 billion spectrum deal that gives SpaceX the rights to deliver direct-to-cell service nationwide — a move tech analyst Jeff Brown says could shape the backbone of the coming space economy and create fortunes on a scale not seen since the rise of NVIDIA.October 17 at 2:00 AM | Brownstone Research (Ad)NextTrip Reports 446% Revenue Surge in Q2 2025October 15 at 5:31 PM | tipranks.comNextTrip’s JOURNY to debut TIDE food, travel seriesOctober 8, 2025 | msn.comNextTrip Converts Promissory Notes to Preferred StockSeptember 19, 2025 | msn.comSee More NextTrip Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like NextTrip? Sign up for Earnings360's daily newsletter to receive timely earnings updates on NextTrip and other key companies, straight to your email. Email Address About NextTripNeurotrope, Inc., a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. The company's lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. It also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases. The company has a license agreement with The Board of Trustees of the Leland Stanford Junior University for the use of bryostatin structural derivatives, known as bryologs, for use in the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection, and traumatic brain injury; and a license agreement to an accelerated synthesis of bryostatin-1. Neurotrope, Inc. also has a cooperative research and development agreement with the National Cancer Institute for the research and clinical development of Bryostatin-1. The company was founded in 2012 and is based in New York, New York.View NextTrip ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Goldman Sachs Earnings Tell: Markets Seem OkayWhy Congress Is Buying Intuitive Surgical Ahead of Earnings3 Reasons to Buy Sprouts Farmers Market Ahead of EarningsTesla Earnings Loom: Bulls Eye $600, Bears Warn of $300Spotify Could Surge Higher—Here’s the Hidden Earnings SignalBerkshire-Backed Lennar Slides After Weak Q3 EarningsWall Street Eyes +30% Upside in Synopsys After Huge Earnings Fall Upcoming Earnings Intuitive Surgical (10/21/2025)Nasdaq (10/21/2025)Netflix (10/21/2025)Texas Instruments (10/21/2025)Citigroup (10/21/2025)Chubb (10/21/2025)Capital One Financial (10/21/2025)Danaher (10/21/2025)Elevance Health (10/21/2025)GE Aerospace (10/21/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
